Abstract Several lines of evidence indicate
Introduction
Excitotoxicity, i.e., excessive stimulation of glutamate receptors leading to ''axon-sparing'' nerve cell death (Olney et al. 1975) , likely plays a central role in the pathogenesis of several neurological disorders including epilepsy, stroke and chronic neurodegenerative diseases (Schwarcz et al. 1984) . The cascade of neurodestructive events might be triggered by glutamate itself or by a number of other endogenous excitotoxins. The most potent of these agents is quinolinic acid (QUIN), a selective NMDA receptor agonist and product of the kynurenine pathway (KP) of tryptophan degradation. Endogenous QUIN has been most comprehensively linked to the pathophysiology of Huntington's disease (HD) but there is also credible evidence for its role in Alzheimer's disease, amyotrophic lateral sclerosis and other catastrophic CNS diseases (see Németh et al. 2006; Chen and Guillemin 2009; Schwarcz et al. 2010 , for recent reviews). The metabolic fate of QUIN, especially the mechanism(s) regulating its disposition and function in the brain, have therefore attracted significant attention from biochemists and neuroscientists alike.
In the brain as in peripheral organs, QUIN biosynthesis is catalyzed by 3-hydroxyanthranilic acid 3,4-dioxygenase (3HAO) (Long et al. 1954; Foster et al. 1986 ). 3HAO transforms the KP metabolite 3-hydroxyanthranilic acid (3HANA) into an unstable intermediate (2-amino-3-carboxymuconic acid semialdehyde; Wiss and Bettendorf 1956) , which rearranges spontaneously to yield QUIN. In the brain, the formation of QUIN from 3HANA, which has been verified in vivo (Speciale et al. 1989) , takes place preferentially in microglial cells (Alberati-Giani et al. 1996; Lehrmann et al. 2001) . 3HAO activity-and QUIN production-is therefore increased in situations where microglial cells are activated, for example following immune stimulation, during ongoing neuronal deterioration or as a consequence of neuronal loss (Schwarcz et al. 1988 Saito et al. 1993; Hutton et al. 2008) .
Microglial cells are increasingly viewed as active participants in neurodegenerative phenomena, and several cellular and molecular mechanisms have been implicated (Block and Hong 2005; Sugama et al. 2009 ). One of the most persuasive arguments has been made for a critical role of iron. An excess of free iron in microglia, by catalyzing the Fenton reaction, leads to the generation of highly reactive free radical species, oxidative stress, and subsequent lipid peroxidation and neuronal damage (Saleppico et al. 1996; Sian-Hülsmann et al. 2011) . Activated microglial cells are less efficient in maintaining iron homeostasis, so that iron-induced oxidative damage is amplified (Shoham and Youdim 2000) . This dysregulation has been traced to the iron storage protein ferritin, which is responsible for the intracellular sequestration of iron (Yoshida et al. 1995 (Yoshida et al. , 1998 . Notably, brain ferritin is abundant in microglial cells (Kaneko et al. 1989) , and dystrophic microglial cells in HD and Alzheimer's disease are associated with ferritin immunoreactivity (Simmons et al. 2007; Lopes et al. 2008) . These findings, together with the fact that abnormally high iron levels are seen-and seen early-in vulnerable brain regions in HD and other neurodegenerative diseases (Dexter et al. 1991; Götz et al. 2004; Bartzokis et al. 2007 ), led to the hypothesis that aberrant regulation of microglial iron disposition may be crucial to the disease process. Furthermore, several studies in animals showed remarkable neuroprotection by iron chelation in relevant disease models, revealing promising therapeutic implications of the ''iron hypothesis'' (Zecca et al. 2004; Li et al. 2011) .
As Fe 2? is a co-factor of 3HAO (Long et al. 1954 ), fluctuations in microglial iron levels might determine enzyme activity and, by extension, control the function of QUIN in the brain under both physiological and pathological conditions. We therefore decided to study the Fe 2? dependence of 3HAO in detail in vitro, using tissue homogenates obtained from mouse, rat and human brain. In all cases, including assessment of tissue from HD patients, we also evaluated the effects of ferritin and the synthetic iron chelator N,N 0 -bis(2-hydroxybenzyl) ethylenediamine-N,N 0 -diacetic acid (HBED), which provides effective neuroprotection in vivo (Bergeron et al. 1999; Liang et al. 2008) .
Methods

Animals
FVB/N mice (Taconic, Hudson, NY, USA) and SpragueDawley rats (Charles River Laboratories, Wilmington, MA, USA) were housed in a temperature-controlled, AAALAC-approved animal facility at the Maryland Psychiatric Research Center on a 12/12 h light-dark cycle with free access to food and water. Animals were killed according to protocols approved by the Institutional Animal Care and Use Committee of the University of Maryland School of Medicine. Brains were then rapidly removed, dissected, and frozen on dry ice.
Human brain tissue
Cortical tissue specimens were obtained from the Maryland Brain Collection, a repository of post-mortem tissue maintained in cooperation with the Office of the Chief Medical Examiner of the State of Maryland and located at the Maryland Psychiatric Research Center. Brain donors (n = 3) were aged 40.0 ± 11.9 years and free of neurological or psychiatric disorders at the time of death. The postmortem interval was 18.0 ± 6.0 h (both means ± SEM).
Striatal tissue from grade 4 Huntington's disease (HD) patients and matched controls were received from the Harvard Brain Tissue Resource Center at McLean Hospital (n = 4 per group). Brain donors were aged 47.8 ± 9.4 years (controls) and 51.8 ± 11.1 years (HD) at the time of death. The postmortem interval was 20.0 ± 2.2 h (controls) and 19.1 ± 1.3 h (HD) (all means ± SEM).
All human tissues were obtained and used in accordance with the Ethical Principles for Medical Research Involving Human Subjects (Declaration of Helsinki).
Cortical and striatal tissue blocks were stored at -80°C until analysis was performed.
Chemicals
Ferritin (containing both the L-and the H-subunit; cf. ''Discussion'') derived from human liver was purchased from EMD Chemicals (Gibbstown, NJ, USA ''), ferritin, or HBED were added in small aliquots as needed. The final incubation volume was 200 lL. The enzyme reaction was terminated by the addition of 50 lL of 6% perchloric acid, and the product, 14 C-QUIN, was recovered by ion-exchange chromatography (Dowex 50, H ? -form) and quantitated by liquid scintillation spectrometry (Foster et al. 1986 ). Blanks were obtained using 10 lM 4-chloro-3-hydroxyanthranilic acid, a specific inhibitor of 3HAO activity (Parli et al. 1980) .
Glutamic acid decarboxylase (GAD)
Tissues were homogenized 1:5 (wt/vol) by sonication in ultrapure water and further diluted in 100 mM Tris-HCl buffer, pH 7.4, containing 0.2% Triton X-100 for a final tissue dilution of 1:10. Twenty-five microliter of the homogenate was then incubated for 1 h at 37°C in 100 mM phosphate buffer, pH 6.9, containing 1 mM disodium EDTA, 50 lM mercaptoethanol, 100 lM pyridoxal-5 0 -phosphate, and 0.045 lCi [
14 C]-glutamic acid in 13 mM monosodium glutamate. The reaction was terminated by the addition of 200 lL of 30% trichloroacetic acid. The 14 CO 2 generated by the enzyme reaction was trapped using filter paper moistened with 200 lL benzethonium hydroxide, and radioactivity was quantified by liquid scintillation spectrometry. Blanks were obtained by adding 25 lL of the phosphate buffer containing disodium EDTA in place of the tissue homogenate.
Protein measurement
Protein was determined by the method of Lowry et al. (1951) , using bovine serum albumin as a standard.
Results
Fe
2? -dependency of brain 3HAO activity
Absolute enzyme activities in cortical tissue in the absence of exogenously supplied Fe 2? were 5.8 ± 0.3 (rat), 3.9 ± 0.0 (mouse) and 26.9 ± 6.9 (human) pmoles/h/mg tissue, respectively. As illustrated in Fig. 1 (Fig. 1) .
Effects of ferritin
Next, we examined the effects of ferritin on 3HAO activity in the absence or presence of exogenously supplied Fe 2? . As shown in Table 1 , ferritin, added at 1, 3, 10, 30 and 100 lg/assay tube in the absence of supplemental Fe 2? , reduced 3HAO activity up to 60%. Although the data did not attain statistical significance in the mouse cortex, the results were significant in rat (10-100 lg ferritin) and human (1-100 lg ferritin) brain tissue homogenate (p \ 0.005-0.0001; repeated measures one-way ANOVA).
Ferritin also attenuated the stimulation of 3HAO activity by exogenously supplied Fe 2? . Tested against maximally effective doses of Fe 2? (cf. Fig. 1 ; 30 lM in rat and human, 40 lM in mouse), the addition of ferritin dose-dependently reduced 3HAO stimulation in all three species. Although moderate quantitative differences were seen between rat, mouse and human enzyme, 30 lg ferritin caused complete reversal to control activity, and 100 lg ferritin resulted in enzyme activities below control levels in all cases (Fig. 2) . Repeated measure one-way ANOVAs revealed an overall significance of p \ 0.001 in all three species.
Effects of HBED An identical experimental protocol was used to examine the ability of the synthetic iron chelator HBED to attenuate the increase in cortical 3HAO activity caused by 30 lM (rat, human) or 40 lM (mouse) Fe 2? . In contrast to ferritin (see above), addition of HBED up to a concentration of 100 lM in the absence of exogenously supplied Fe 2?
failed to reduce 3HAO activity in any species (data not shown). However, addition of HBED (1-100 lM) caused steep, dose-dependent reductions in Fe 2? -stimulated 3HAO. The effect was very similar in all three species, with 30 and 100 lM HBED providing significant attenuation (Fig. 3, insets) . Repetition of the experiments using six HBED concentrations within a narrow range, i.e., between 10 and 30 lM, gave similar results in rat, mouse and human brain homogenates (Fig. 3) . Statistical analysis of the effect showed an overall significance of p \ 0.001 (repeated measures one-way ANOVA).
Fe 2? -dependency of 3HAO activity in the human neostriatum: normal controls and HD Since abnormal disposition of iron and/or QUIN may be linked to the pathophysiology of HD (Bartzokis et al. 2007; Schwarcz et al. 2010) , we next determined the Fe 2? -dependence of 3HAO using neostriatal tissue (used in the assay at a final dilution of 1:250 to avoid a ceiling effect) obtained postmortem from individuals with end-stage (grade 4) HD and normal controls (n = 4 each). Compared to control specimens, HD tissue showed the expected large decrease in GAD activity ( Fig. 4a ; p \ 0.05, unpaired t test), confirming massive neuronal degeneration (Bird and Iversen 1974) . In the same tissues, 3HAO activity in the presence of 150 lM Fe 2? , i.e., the concentration routinely used to obtain optimal enzyme activity in vitro (Schwarcz et al. 1988) , was higher in HD (375.0 ± 132.7 vs. 122.0 ± 22.9 pmol/h/mg protein), though the group difference did not attain statistical significance ( Fig. 4a ; p = 0.11, unpaired t test).
Next, we assessed striatal 3HAO activity in the same tissues in the absence and presence of externally supplied Fe 2? (30 lM; cf. Fig. 1 ). In the absence of added Fe 2? , 3HAO activities were 74.0 ± 15.7 (control) and 84.7 ± 24.5 (HD) pmoles/h/mg tissue. Addition of 30 lM Fe 2? caused an approximately threefold increase in enzyme activity in both control and HD tissue (Fig. 4b) .
In the presence of 30 lM Fe 2? , addition of ferritin or HBED had similar effects in both HD and control tissue (Fig. 4b) . Thus, whereas neither 10 lg of ferritin nor 10 lM HBED affected the stimulation of 3HAO activity by Fe 2? significantly in either case, the chelators had a substantive effect at 100 lg or 100 lM, respectively, reducing 3HAO activity to control levels (absence of added Fe 2? ) or below in both groups. With the exception of 100 lM HBED in HD tissue, all these effects attained statistical significance (repeated measures one-way ANOVA followed by Bonferroni's post hoc analysis). Change scores, i.e., the effect of the iron chelators relative to the respective control value (30 lM Fe 2? ), did not reveal differences between normal control and HD tissue (Student's t test).
Discussion
Using crude tissue homogenates and a conventional radiochemical assay procedure (Foster et al. 1986 ), the present in vitro study was designed to investigate in detail the potential of Fe 2? to regulate 3HAO activity in the brain. Our results revealed that even relatively minor fluctuations in Fe 2? concentration in the assay mixture had significant effects on 3HAO in all three species tested (rat, mouse and human), suggesting that Fe 2? is capable of fine tuning cerebral QUIN production. The slope of the iron curve was steepest in rat brain where a fairly modest increase-from 6 to 14 lM-resulted in a more than fivefold stimulation of enzyme activity. In all species, the Fe 2? -induced increase in 3HAO activity was dose-dependently attenuated by the addition of ferritin, the main iron storage protein in the brain. Moreover, the effect of iron was also readily prevented by micromolar concentrations of N,N 0 -bis(2-hydroxybenzyl) ethylenediamine-N,N 0 -diacetic acid (HBED), a cell membrane-permeable, experimental iron chelator with impressive neuroprotective properties in vivo (Liang et al. 2008 ). Finally, we compared the effects of iron and iron chelation on 3HAO activity in neostriatal specimens obtained from HD patients and normal controls. This attempt to relate our study to the roles of both Fe 2? and QUIN in the pathophysiology of HD failed to reveal significant abnormalities in the diseased tissue.
Iron homeostasis is critical for normal brain function, and several mechanisms have evolved to control the disposition of the metal in cerebral tissue. Iron uptake from the blood, its storage and release within the brain, as well as iron efflux from the brain, are tightly regulated by a host of proteins, including divalent metal transporters, transferrin and its receptors, and a number of additional ironbinding proteins. Although the biochemistry and cell biology of several of these proteins are reasonably well understood individually, their joint role in controlling intracellular trafficking and physiological functions of iron in the brain is highly complex and has not been clarified (see Burdo and Connor 2003 and Ke and Qian 2007 , for reviews). Notably, however, the ambient cytosolic concentration of free iron in the normal rat brain is approximately 30 lM, i.e., in the range used experimentally to modulate 3HAO in the present study (Erikson et al. 1997 ).
In the brain as elsewhere in the body, ferritin is the major protein involved in the storage and release of intracellular iron and therefore controls the many functions of iron, ranging from oxygen transport to DNA synthesis (Ponka et al. 1998) . By effectively sequestering iron as soluble, ''mineralized'' ferrihydrite, ferritin protects the cell against the production of destructive oxygen radicals and at the same time provides ferrous ions for biological functions. Widely distributed within the cell, ferritin consists of a protein shell that is made of two distinct polypeptide subunits [H (heavy) and L (light)] and encloses a hollow interior where bioavailable iron is stored. The two chains fulfill distinct, yet synergistic roles in the handling of intracellular iron, with the H-subunit accounting for the rapid accumulation and subsequent oxidation of Fe 2? to Fe 3? , and the L-subunit serving a conventional storage function (Koorts and Viljoen 2007) . Of interest in the present context, microglia express mostly L-ferritin (Connor et al. 1994) , possibly affecting access of endogenous reducing agents such as cysteine, glutathione and ascorbic acid, and the subsequent transport of ferrous ions to various intracellular sites (see Koorts and Viljoen 2007, for review) . Thus, while ferritin can be used experimentally as (repeated measures one-way ANOVA followed by Bonferroni's post-hoc analysis). See text for absolute enzyme activities in the absence of ferritin (100%) Regulation of quinolinic acid 127 an iron chelator, its biological role is clearly far more multi-faceted and versatile. Not unexpectedly, in light of its central role in the sequestration of brain iron, abnormal ferritin has detrimental . Control enzyme activities in the presence of Fe 2? were 30.4 ± 3.3 (rat), 22.2 ± 1.2 (mouse) and 114.9 ± 10.8 (human) pmoles/h/mg tissue, respectively. *p \ 0.05, **p \ 0.01, ***p \ 0.001 versus enzyme activity in the presence of 30 lM (rat, human) or 40 lM (mouse) Fe 2? , respectively (repeated measures one-way ANOVA followed by Bonferroni's post-hoc analysis) effects on brain structure and function. This was originally shown by Curtis et al. (2001) , who reported the occurrence of extrapyramidal features similar to HD in affected individuals from a family with a mutation in the gene coding for L-ferritin. Similar features of a hereditary ''ferritinopathy'' were described in a different pedigree (Kubota et al. 2009) , and the phenotype was duplicated in mice expressing a mutant form of L-ferritin and traced to iron mishandling on the molecular level (Vidal et al. 2008; Baraibar et al. 2010; Luscieti et al. 2010) . However, abnormal iron function has also been associated with the genes of H-ferritin and several other proteins involved in iron metabolism and trafficking. Clinical implications of these gene findings have so far focused primarily on HD and, in particular, Alzheimer's and Parkinson's disease (see Zecca et al. 2004 and Rhodes and Ritz 2008, for review) .
The present study, demonstrating a tight regulation of QUIN neosynthesis by Fe 2? concentrations in the endogenous range, suggests additional, underappreciated mechanisms by which impaired intracellular iron disposition might lead to brain dysfunction and neurodegeneration. Thus, while the Fe 2? dependency of 3HAO is well characterized (Long et al. 1954; Koontz and Shiman 1976; Dilović et al. 2009 ), direct interactions between free iron and QUIN, too, might be causally involved in pathology. In addition to its ability to selectively activate the NMDA subtype of glutamate receptors (see ''Introduction''), QUIN potently stimulates lipid peroxidation (Rios and Santamaria 1991) , and this effect, which is strictly dependent on the presence of ferrous ions (Stípek et al. 1997) , potentiates QUIN-induced excitotoxicity (Santamaría et al. 2001) . Notably, the generation of reactive oxygen species by QUIN is secondary to the formation and slow, pH-dependent autooxidation of Fe 2? -QUIN complexes and can be readily prevented by iron chelation (Pláteník et al. 2001; Dairam et al. 2008) . Finally, to complicate matters further, endogenous iron also appears to directly control the binding of QUIN to the NMDA receptor (St'astny et al. 1999) . By inference, our present results imply that 3HAO, by factually determining the ratio between free iron and QUIN in the cell, plays a central role in controlling the highly complex interplay between Fe 2? and QUIN in the mammalian brain. The physiological significance of the balance of free iron and QUIN in the brain has so far not been interrogated in detail, however.
Microglial cells may hold the key to the puzzle since they contain 3HAO and are richly endowed with ferritin (Kaneko et al. 1989; Alberati-Giani et al. 1996; Lehrmann et al. 2001) . Following nerve cell loss or an immune challenge, activated or dystrophic microglia show intense ferritin immunoreactivity in both animals and humans (Gorter et al. 2005; Zhang et al. 2005; Simmons et al. 2007; Lopes et al. 2008) . Similarly, and coincident with increased 3HAO activity measured in tissue homogenate , microglial QUIN immunoreactivity is dramatically enhanced in the excitotoxically lesioned rat striatum, which models neostriatal HD pathology (Lehrmann et al. 2001) . In spite of these remarkable changes, our present in vitro experiments revealed neither qualitative nor quantitative differences between the effects of iron or iron chelation on neostriatal 3HAO activity in tissue from normal controls and HD patients (Fig. 4) . Ongoing in vivo experiments in our laboratory are designed to elaborate the dynamics between microglial iron and QUIN in greater depth and, in particular, to determine the potential relevance of these interactions for neuronal dysfunction and death.
Our study also pertains to the use of iron chelators as therapeutic agents in human brain diseases. Interestingly, the most impressive neuroprotective effects of iron chelation, including genetic up-regulation of ferritin (Kaur et al. 2003) , have so far been seen in animal models of Parkinson's disease, Alzheimer's disease and HD, i.e., disorders which have been linked to excitotoxic mechanisms and, specifically, to excess QUIN (Zecca et al. 2004; Nguyen et al. 2005; Németh et al. 2006; Chen and Guillemin 2009; Schwarcz et al. 2010; Li et al. 2011 ). Our results with ferritin and HBED, a synthetic, membrane-permeable chelator of mitochondrial iron with striking in vivo potency (Bergeron et al. 1999; Liang et al. 2008) , raise the possibility that dysregulation of iron storage mechanisms in the brain may contribute to the neuropathology of QUIN-related neurodegenerative disorders. Conversely, down-regulation of QUIN synthesis may contribute to the neuroprotective effects of iron chelation in vivo.
